EGFR signaling pathway in breast cancers: From traditional signal transduction to direct nuclear translocalization

Breast Cancer Research and Treatment

Volumn 95, Issue 3, 2006, Pages 211-218

  Lo, Hui Wen ^a   Hsu, Sheng Chieh ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Epithelial growth factor receptor (EGFR); STAT3; Transcriptional regulation

Indexed keywords

CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; RAS PROTEIN; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CELL SURFACE; CELL TRANSPORT; GENE ACTIVITY; GENE TARGETING; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH;

BREAST NEOPLASMS; CELL NUCLEUS; EPIDERMAL GROWTH FACTOR; HUMANS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33645217263     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9011-0     Document Type: Review

References (129)

1. Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237: 1555-1562, 1962
2. Gregory H: Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257: 325-327, 1975
3. Cohen S, Carpenter G: Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci USA 72: 1317-1321, 1975
4. Cohen S, Carpenter G, King L Jr.: Epidermal growth factor-receptor- protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255: 4834-4842, 1980
5. Cohen S, Ushiro H, Stoscheck C, Chinkers M: A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257: 1523-1531, 1982
6. Cohen S, Carpenter G, King L Jr.: Epidermal growth factor-receptor- protein kinase interactions. Prog Clin Biol Res 66(Pt A): 557-567, 1981
7. Cohen S, Fava RA, Sawyer ST: Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. Proc Natl Acad Sci USA 79: 6237-6241, 1982
8. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880, 1980
9. Arteaga Ca: Targeting HER1/EGFR: A molecular approach to cancer therapy. Seminars in Oncology 30: 3-14, 2003
10. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760, 1984
11. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983
12. Patnaik A, Beeram M, de Bono JS, Mita A, Chu SC, Rowinsky EK, Schwartz G, O'Rourke P, Takimoto CH, Tolcher AW: Phase I and Pharmacokinetics (PK) of Combined erbB1 and erbB2 Blockade with OSI-774 (Erlotinib; E) and Trastuzumab (T) in Combination with Weekly Paclitaxel (P) in Patients (pts) with Advanced Solid Tumors. Proceedings of American Society of Clinical Oncology Annual Meeting, Abstract No: 2000, 2005
13. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Ali S, Slade MJ, Shousha S, Morrisson K, Coombes RC: Antiproliferative and molecular effects of neoadjuvant (pre-operative) gefitinib alone or in combination with anastrozole in epidermal growth factor receptor (EGFR) positive, estrogen receptor alpha (ERa) positive patients with primary breast cancer. Proceedings of American Society of Clinical Oncology Annual Meeting, Abstract No: 552, 2005
14. Ciardiello F, Troiani T, Caputo F, de Laurentiis M, Tortora G, Palmieri G, de Vita F, Colantuoni G, de Placido S, Bianco A: Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer. Proceedings of American Society of Clinical Oncology Annual Meeting, Abstract No: 3080, 2005
15. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, Soori GS, Sabagh TM, Perez EA: N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). Proceedings of American Society of Clinical Oncology Annual Meeting, Abstract No: 644, 2005
16. Arteaga CL, Baselga J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell 5: 525-531, 2004
17. Twombly R: Failing survival advantage in crucial trial, future of Iressa is in jeopardy. J Natl Cancer Inst 97: 249-250, 2005
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004
20. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004
21. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004
22. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757, 2005
23. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882, 2005
24. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY: EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64: 1444-1445, 2005
25. Su MC, Lien HC, Jeng YM: Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 224: 117-121, 2005
26. Cohen S, Taylor JM: Epidermal growth factor: chemical and biological characterization. Recent Prog Horm Res 30: 533-550, 1974
27. Haigler HT, McKanna JA, Cohen S: Direct visualization of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol 81: 382-395, 1979
28. Carpenter G: ErbB-4: mechanism of action and biology. Exp Cell Res 284: 66-77, 2003
29. Park OK, Schaefer TS, Nathans D: In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci U S A 93: 13704-13708, 1996
30. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98: 7319-7324, 2001
31. Barre B, Avril S, Coqueret O: Opposite regulation of myc and p21wafl transcription by STAT3 proteins. J Biol Chem 278: 2990-2996, 2003
32. Anderson D, Koch CA, Grey L, Ellis C, Moran MF, Pawson T: Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science 250: 979-982, 1990
33. Navolanic PM, Steelman LS, McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 22: 237-252, 2003
34. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000
35. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF: Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148: 549-558, 1996
36. Craven RJ, Lightfoot H, Cance WG: A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol 12: 39-49, 2003
37. Baselga J, Norton L: Focus on breast cancer. Cancer Cell 1: 319-322, 2002
38. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr.: Stat3 as an oncogene. Cell 98: 295-303, 1999
39. Petrocelli T, Slingerland JM: PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res 3: 356-360, 2001
40. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A, Liu FF: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104: 195-203, 2003
41. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001
42. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001
43. Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Cliem 277: 11352-11361, 2002
44. Kumar R, Hung MC: Signaling intricacies take center stage in cancer cells. Cancer Res 65: 2511-2515, 2005
45. El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 3: E71-73, 2001
46. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S: Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 21: 5644-5657, 2001
47. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, Houghton PJ: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11: 1491-1501, 2003
48. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC: Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10: 3815-3824, 2004
49. Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL, Norbury CJ: Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer, association with prognosis. Eur J Cancer 37: 2405-2412, 2001
50. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002
51. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152, 2002
52. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144, 2002
53. Clarke RB: p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res 5: 162-163, 2003
54. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997
55. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003
56. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y: Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843-21850, 2002
57. Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603, 2001
58. Turkson J, Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000
59. Darnell JE Jr.: STATs and gene regulation. Science 277: 1630-1635, 1997
60. Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004
61. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001
62. Fernandes A, Hamburger AW, Gerwin BI: ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83: 564-570, 1999
63. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956, 2003
64. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994
65. Fu XY: From PTK-STAT signaling to caspase expression and apoptosis induction. Cell Death Differ 6: 1201-1208, 1999
66. Yang E, Lerner L, Besser D, Darnell JE Jr: Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278: 15794-15799, 2003
67. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11: 709-719, 1999
68. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R: Induction of p2IWAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19: 5419-5427, 2000
69. Karni R, Jove R, Levitzki A: Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18: 4654-4662, 1999
70. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, Horvath CM, Ronai Z: Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7: 517-528, 2001
71. Lo H-W, Hsu S-C, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih J-Y, Hung M-C: Nuclear Interaction of EGFR and STAT3 in the Activation of iNOS/NO Pathway. Cancer Cell 7: 575-589, 2005
72. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002
73. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329, 2003
74. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110-3120, 2005
75. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004
76. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R: Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102: 5998-6003, 2005
77. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R: Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3: 1533-1542, 2004
78. Marti U, Burwen SJ, Wells A. Barker ME, Huling S, Feren AM, Jones AL: Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13: 15-20, 1991
79. Marti U, Hug M: Acinar and cellular distribution and mRNA expression of the epidermal growth factor receptor are changed during liver regeneration. J Hepatol 23: 318-327, 1995
80. Marti U, Ruchti C, Kampf J, Thomas GA, Williams ED, Peter HJ, Gerber H, Burgi U: Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11: 137-145, 2001
81. Marti U, Wells A: The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR. Mol Cell Biol Res Commun 3: 8-14, 2000
82. Raper SE, Burwen SJ, Barker ME, Jones AL: Translocation of epidermal growth factor to the hepatocyte nucleus during rat liver regeneration. Gastroenterology 92: 1243-1250, 1987
83. Schausberger E, Eferl R, Parzefall W, Chabicovsky M, Breit P, Wagner EF, Schulte-Hermann R, Grasl-Kraupp B, Chabikovsky M: Induction of DNA synthesis in primary mouse hepatocytes is associated with nuclear pro-transforming growth factor alpha and erbb-1 and is independent of c-jun. Carcinogenesis 24: 835-841, 2003
84. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808, 2001
85. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H: Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21: 277-282, 1990
86. Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125, 1994
87. Lo H-W, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung M-C: Novel prognostic value of nuclear EGF receptor in breast cancer. Cancer Res 65: 338-348, 2005
88. Bourguignon L, Lan K-H, Singleton P, Lin S-Y, Yu D, Hung M-C: Localizing the EGF receptor - Reply. Nat Cell Biol 4: E22-E23, 2002
89. Klein C, Gensburger C, Freyermuth S, Nair BC, Labourdette G, Malviya AN: A 120 kDa nuclear phospholipase Cgamma1 protein fragment is stimulated in vivo by EGF signal phosphorylating nuclear membrane EGFR. Biochemistry 43: 15873-15883, 2004
90. Ni CY, Murphy MP, Golde TE, Carpenter G: Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181, 2001
91. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW: c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 157: 929-939, 2002
92. Xie Y, Hung MC: Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203: 1589-1598, 1994
93. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC: Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6: 251-261, 2004
94. Krolewski JJ: Cytokine and growth factor receptors in the nucleus: What's up with that?. J Cell Biochem 95: 478-487, 2005
95. Ni CY, Yuan H, Carpenter G: Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage. J Biol Chem 278: 4561-4565, 2003
96. Cheng QC, Tikhomirov O, Zhou W, Carpenter G: Ectodomain cleavage of ErbB-4: Characterization of the cleavage site and m80 fragment. J Biol Chem, 278: 38421-38427, 2003
97. Carpenter G: Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 15: 143-148, 2003
98. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H: Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res 48: 7200-7206, 1988
99. Reilly JF, Maher PA: Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol 152: 1307-1312, 2001
100. Maher PA: Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 134: 529-536, 1996
101. Raabe TD, Deadwyler G, Varga JW, Devries GH: Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia 45: 197-207, 2004
102. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, Lasher RS, Jarett L, Olefsky JM: Nuclear translocation of the insulin receptor A possible mediator of insulin's long term effects. J Biol Chem 262: 3362-3368, 1987
103. Zhang FX, Lai CH, Lai SK, Yung KK, Shum DK, Chan YS: Neurotrophin receptor immunostaining in the vestibular nuclei of rats. Neuroreport 14: 851-855, 2003
104. Zwaagstra JC, Guimond A, O'Connor-McCourt MD: Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest. Exp Cell Res 258: 121-134, 2000
105. Chan YS, Chen LW, Lai CH, Shum DK, Yung KK, Zhang FX: Receptors of glutamate and neurotrophin in vestibular neuronal functions. J Biomed Sci 10: 577-587, 2003
106. Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J, Coons S, Stachowiak MK: Nuclear accumulation of fibroblast growth factor receptors in human glial cells association with cell proliferation. Oncogene 14: 2201-2211, 1997
107. Pillai G, Cook N, Turley H. Leek RD, Blasquez C, Pezzella F, Harris AL, Gatter KC: The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study. Histopathology 46: 209-216, 2005
108. Jans DA, Hassan G: Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling?. Bioessays 20: 400-411, 1998
109. Bader T, Weitzerbin J: Nuclear accumulation of interferon gamma. Proc Natl Acad Sci USA 91: 11831-11835, 1994
110. Larkin J, 3rd, Johnson HM, Subramaniam PS: Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma. J Interferon Cytokine Res 20: 565-576, 2000
111. Subramaniam PS, Green MM, Larkin J 3rd, Torres BA, Johnson HM: Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence. J Interferon Cytokine Res 21: 951-959, 2001
112. Subramaniam PS, Johnson HM: Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha. J Immunol 169: 1959-1969, 2002
113. Jans DA, Briggs LJ, Gustin SE, Jans P, Ford S, Young IG: The cytokine interleukin-5 (IL-5) effects cotransport of its receptor subunits to the nucleus in vitro. FEBS Lett 410: 368-372, 1997
114. Curtis BM, Widmer MB, deRoos P, Qwarnstrom EE: IL-1 and its receptor are translocated to the nucleus. J Immunol 144: 1295-1303, 1990
115. Subramaniam PS, Johnson HM: The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett 578: 207-210, 2004
116. Grasl-Kraupp B, Schausberger E, Hufnagl K, Gerner C, Low-Baselli A, Rossmanith W, Parzefall W, Schulte-Hermann R: A novel mechanism for mitogenic signaling via pro-transforming growth factor alpha within hepatocyte nuclei. Hepatology 35: 1372-1380, 2002
117. Kimura H: Schwannoma-derived growth factor must be transported into the nucleus to exert its mitogenic activity. Proc Natl Acad Sci USA 90: 2165-2169, 1993
118. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE: The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 167: 469-478, 2004
119. Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 3-17, 1992
120. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, Milano G: Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12: 841-846, 2001
121. Seshadri R, McLeay WR, Horsfall DJ, McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69: 23-27, 1996
122. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9-S15, 2001
123. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995
124. Lala PK, Orucevic A: Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17: 91-106, 1998
125. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6: 2408-2416, 2000
126. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA: Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6: 4768-4775, 2000
127. Cianchi F, Cortesini C, Fantappie O, Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G, Marzocca C, Perna F, Mazzanti R, Bechi P, Masini E: Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 162: 793-801, 2003
128. Komuro A, Nagai M, Navin NE, Sudol M: WW domain-containing protein YAP associates with ErbB-4 and acts as a cotranscriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278: 33334-33341, 2003
129. Reguly T, Wrana JL: In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol 13: 216-220, 2003